Monte Rosa Therapeutics (GLUE) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Monte Rosa Therapeutics (GLUE) is Moderate Underperform.

The composite score behind that read is -0.24, weighing +0.06 of bullish evidence against -0.27 bearish.

Monte Rosa Therapeutics last closed at $10.17, +3.04% on the session.

Against the IVW growth benchmark the position is +3.20% over the forecast window.

The read is built from 12 underlying insights — 2 bullish and 10 bearish.

Agreement across those insights is 83%.

Monte Rosa Therapeutics has no graded predictions yet. We publish our accuracy across thousands of stocks in the open, misses included.

On the fundamentals StockMap ranks Monte Rosa Therapeutics in the 19th percentile on return on equity, where 100 is best.

Monte Rosa Therapeutics is classified under Health Care / Biotechnology, with a market capitalisation of $842.04M.

StockMap tracks Monte Rosa Therapeutics as the 141st largest of the 377 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 198 Moderate Underperform, 166 Neutral and 13 Strong Underperform.

On that composite Monte Rosa Therapeutics ranks 212th of 377 in the group, against a group median of -0.21.